Collaboration Agreement with Voxcell BioInnovation

Inaphaea is pleased to announce the execution of a collaboration agreement (the "Agreement") with Canada based VoxCell BioInnovation Inc. ("VoxCell") to provide Inaphaea's Patient Derived Cells ("PDC") for evaluation and use in VoxCell's proprietary fully perfusable vascularised 3D tissue culture models. The Agreement initially focusses on establishment of three Triple Negative Breast Cancer ("TNBC") in-vitro 3D tumour models which can then be offered for commercial sale and/or services by VoxCell and/or Inaphaea.

As part of the Agreement, three TNBC PDC models will be expanded and tested/optimised for growth on VoxCell's Bioink matrix at Inaphaea's facility. PDCs will then be transferred to VoxCell to generate vascularised 3D cell culture models and further evaluated. Both parties plan to jointly publish the results.

Mark Eccleston, CEO of ValiRx commented "We continue to build partnerships that expand the markets for our PDC models and testing services, particularly in the ex-vivo space considering the FDA's decision to phase out animal-based testing requirements for new drug filings. This Agreement with VoxCell exemplifies our approach to leverage commercial access to our biobank with services and technologies that complement our internal pipeline development and is a real opportunity to develop valuable data to progress our Clx001 oncolytic peptide asset whilst exemplifying the utility of our PDC models in combination with a next generation, non-animal-based testing platform. VoxCell's perfused 3D culture platform is well positioned for testing aspects of nano-formulated drug delivery such as targeting, tumour accumulation from the vasculature and penetration into solid tumours."

Karolina Valente, CEO of VoxCell commented "We are proud to partner with ValiRx to accelerate the development of physiologically relevant TNBC models. By combining their PDC models with our vascularized 3D bioprinting technology, we will create more predictive, human-like tumour tissues for drug screening. Integrating clinically relevant cells from ValiRx into our high-resolution vascular networks will allow us to support the assessment of ValiRx's Clx001 oncolytic peptide asset in a highly translational environment. This collaboration not only aims to generate valuable efficacy and tumor penetration data for Clx001, but also sets the foundation for expanding our partnership to other cancer indications, leveraging the breadth of ValiRx's PDC model biorepository and VoxCell's advanced, perfused tissue models. Together, we are helping shape a future where complex cancers like TNBC are studied and treated with greater precision and confidence."

Subscribe to our news alert service: https://valirx.com/s/f298d1